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Purpose: Genetic studies were performed to identify the causative mutation in a 15-year-old girl diagnosed with congenital
stationary night blindness (CSNB) presenting Mizuo-Nakamura phenomenon, a typical Oguchi disease symptom. The
patient also had dural sinus thrombosis (DST), thrombocytopenia, and systemic lupus erythematosus (SLE).
Methods: Mutation analysis was done by sequencing two candidate genes, S-antigen (SAG; arrestin 1), associated with
Oguchi type 1, and rhodopsin kinase (GRK1), associated with Oguchi type 2. In addition, the C677T variation in the
methylenetetrahydrofolate reductase (MTHFR) gene was also screened in the family, to determine its probable association
with hyperhomocysteinemia in the patient.
Results: Sequencing of the SAG and GRK1 resulted in identifying a novel homozygous nonsense mutation (c.916G>T;
p.Glu306*) in SAG, which in unaffected siblings either was present in a heterozygous state or absent. The C677T
heterozygous allele in the MTHFR gene was found to be associated with hyperhomocysteinemia in the patient and other
family members.
Conclusions: This is the first report of Oguchi type 1 in a Pakistani patient due to a nonsense mutation (c.916G>T;
p.Glu306*) in SAG. The neurologic and hematological abnormalities likely are not associated with the SAG variant.
Oguchi  disease  is  a  congenitally  inherited  non-
progressive  disease  of  the  retinal  rod  photoreceptor  cells
characterized by stationary night blindness in which patients
usually possess normal visual acuity, visual field, and color
vision. The distinctive attribute of the disease is the Mizuo-
Nakamura phenomenon, which is characterized by a diffuse
yellow or gray coloration of the retina that is absent when the
rod cells are dark-adapted but reappears shortly after exposure
to light [1,2]. Based on mutations in two genes, namely, the
arrestin (also called S-antigen, SAG) and rhodopsin kinase
(also called G-protein-dependent receptor kinase 1, GRK1)
[3–6], the disease is classified as type 1 or type 2, respectively.
Of these two genes, SAG acts as an inhibitor of the activated
phototransduction  cascade  where  the  gene  binds  to  the
photoactivated-phosphorylated  rhodopsin,  thereby
preventing  the  transducin-mediated  activation  of
phosphodiesterase, thus making it a vital factor in the recovery
phase of phototransduction [7].
SAG is expressed not only in the retina, specifically in the
rod photoreceptor cell outer segment, but also in the pineal
gland where the gene’s function still needs to be elucidated
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[8]. The SAG protein consists of 405 amino acids encoded by
a gene consisting of 16 exons of which 15 are coding. To date,
three  nonsense  mutations  and  a  frameshift  mutation  (c.
926delA;  p.N309Tfs*12),  previously  annotated  as  c.
1147delA, have been reported. The latter variant is the most
frequent cause of Oguchi disease in Japanese patients [4,9–
11]. The same mutation has been shown to be associated with
retinitis pigmentosa [12]. In addition a mutation in SAG has
been described previously as causing Oguchi disease in an
Indian  family  [13].  In  the  Pakistani  population,  GRK1
mutations have been reported to cause not only the typical
form of the disease (type 2) but also its variant types [14,15].
However, to date no SAG mutations have been shown to cause
Oguchi disease in Pakistani patients. We report here a novel
homozygous nonsense mutation in SAG in an individual with
Oguchi disease and multiple neurologic and hematological
disorders.
METHODS
Ethics committee approval and patient recruitment: The study
was conducted after approval was obtained from the Shifa
College  of  Medicine/Shifa  International  Hospital  Ethics
Committee/Institutional  Review  Board.  The  medical  and
family history of the patient was recorded, and blood samples
were collected from the patient and family members after they
had given their informed written consent for participation in
the study.
Molecular Vision 2012; 18:1253-1259 <http://www.molvis.org/molvis/v18/a131>
Received 14 November 2011 | Accepted 7 May 2012 | Published 12 May 2012
© 2012 Molecular Vision
1253Clinical presentation and patient history: A 15-year-old girl
with bilateral eye pain and headache on reading and non-
progressive blurring of distance and near vision, especially in
the  dark,  was  referred  by  a  neurologist.  A  detailed
ophthalmological examination was performed that included
visual field analysis, visual acuity testing, as well as dark
adaptation and electroretinography (ERG).
In addition to Oguchi disease, the patient was diagnosed
with dural sinus thrombosis (DST), thrombocytopenia, and
systemic lupus erythematosus (SLE).
Genetic analysis: To identify the genetic cause of the disease
in the patient, blood samples were collected by venipuncture
in  EDTA  vacutainer  tubes  (Becton  Dickinson,  Franklin
Lakes, NJ) from the patient and the available family members
(Figure 1). The samples were stored at 4 °C till DNA isolation
was performed as described previously [16]. Oguchi disease
candidate  gene  analysis  was  performed  in  the  family  by
sequencing SAG and GRK1. The latter gene was sequenced
by using the primers and conditions as described previously
[14,15].To sequence SAG     (NM_000541.4), primers flanking
exons  and  splice  sites,  which  included  exon-intron
boundaries,  were  designed,  and  the  genomic  DNA  was
amplified with PCR using the primers and conditions given in
Table 1. The PCR products were purified with the GeneJET
PCR  purification  kit  (Fermentas,  Glen  Burnie,  MD)  and
sequenced  with  the  help  of  dye-termination  chemistry
(BigDye  Terminator,  version  3  on  a  3730  or  2100  DNA
analyzer; Applied Biosystems, Foster City, CA) and the same
primers as used in PCR amplification. Carrier screening of the
identified mutation in the family was also performed with
sequence analysis of exon 11 in all family members.
Healthy  control  panel  screening  was  performed  with
polymerase  chain  reaction-restriction  fragment  length
polymorphism analysis; the presence of the mutant residue T
at position c.916 in exon 11 abolishes a recognition site of
BssSI. PCR was performed using the primers and conditions
Figure 1. Family pedigree and mutation
segregation. Pedigree of the patient and
her  family  where  the  white  circles
represent  normal  women,  the  filled
circle  the  affected  woman,  and  white
squares  normal  men.  Deceased
individuals are shown with a slanted line
across the symbol. The segregation of
mutation is also shown where the mutant
nucleotide  c.916T  is  depicted  in  red
lettering; the wild-type c.916G in green
lettering.
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1254as described above, which resulted in the generation of a 288
bp fragment. Individuals carrying the ancestral allele upon
digestion with BssSI gave two fragments (186 bp and 102 bp),
while in individuals carrying the variant allele the 288 bp
fragment remained undigested.
Methylenetetrahydrofolate  reductase  gene  analysis  for
hyperhomocysteinemia: A raised serum homocysteine level
has been reported to be associated with C677T variation in the
methylenetetrahydrofolate reductase (MTHFR) gene, in the
homozygous  as  well  as  heterozygous  state;  therefore,  we
assessed the family members by genotyping them for this
variation  [17]  and  determining  their  homocysteine  levels
[18]  to  find  any  probable  role  of  this  single  nucleotide
polymorphism (SNP) in causing hyperhomocysteinemia in
the patient.
RESULTS
Ophthalmological examination showed that the uncorrected
visual  acuity  of  the  patient  (V:1)  was  6/9  for  both  eyes.
Ophthalmoscopy  showed  static  hemeralopia  (which  is
clinically correlated to the side effect of medication) with a
grayish-yellow metallic sheen of the fundus in the peripheral
area (Figure 2A). The photopic ERG was normal while the
scotopic ERG of the patient showed significantly reduced rod
response (data not shown). After prolonged dark adaptation,
the  grayish-yellow  fundus  appearance  reverted  to  normal
(Figure 2B), which is typical in patients with Oguchi disease.
The non-ocular features, that is, neurologic symptoms in
concordance  with  DST,  included  nausea,  depression,  and
epistaxis.  A  brain  computerized  axial  tomography  scan
showed extensive venous infarcts in the right cerebellum,
pons, midbrain, right thalamus, and temporal lobe, as well as
diffuse brain edema. Within this infarcted area, an interval
development of hemorrhage in the right basal ganglia was also
noted.  The  patient’s  hematological  reports  for  the  SLE
diagnosis revealed elevated prothrombin time (latest 16 s) and
a platelet count of 137,000. Her rheumatology reports showed
negative lupus anticoagulant, elevated anti-dsDNA of 83 IU/
ml,  and  positive  antinuclear  antibody.  Her  fasting  serum
homocysteine was also raised 21.4 μmole/l (normal range: 4–
15 μmole/l), while her protein C, glucose random, and lactate
dehydrogenase levels were normal. In addition, she had malar
erythema and ankle edema.
TABLE 1. SEQUENCING PRIMERS FOR SAG AND AMPLIFICATION CONDITIONS.




SAG-EX2 TGTCTTACCTTTCTCCAACCC CCCTCAAAGAGTTTTGATGTTG 59 254
SAG-EX3 TATTGGCCAGGCTCAAACTC TTGTTTCCAATCAGCCAGTG 59 381
SAG-EX4 CCTTTGCCTGACTTTTCTTTC CCTCTGCCTTCCTGTCTCTC 59 291
SAG-EX5 CCATTCCGTCAGTGGTGG CTATCCCCTTTCCTTTGCC 59 344
SAG-EX6 AGGCAGGAAATTTTGGGAAG CACTTGAGCCCAGAAACCAC 55 400
SAG-EX7 ATCATGTGCCCTGTGTGAG ACAGAGACAAGGTGGAGGTC 52 246
SAG-EX8 TGACAGTGGGGAGAGAACAG TGAAGAGAGGGGTGTGGG 55 286
SAG-EX9 TTCCAGTGAAAGGGATTGAG GTGACCTCTCAGGAAACAGG 52 254
SAG-EX10 GGAGAGACCAGCGTGTACC CTTCTTCAGCAATAAACGGC 59 246
SAG-EX11 TGCCTAATGTCAAATAGGGG TGATGTGAAGGGAAGCAGAC 59 288
SAG-EX12 CTCGAATGGAAAGGCTGC CAGGAAAGGAAAAGTTCAGAC 55 228
SAG-EX13 TCTGAATCATGGGAAAGGG AGAAACCGTTTTGGAGCC 59 173
SAG-EX14 GGATCTTTTGTGACTCTCCG GAGATGCGGTCAAGAAAGAC 59 242
SAG-EX15 CATGAACTGCATGTATCTAGGC TAAGCACTAGGGAGCAGACG 58 315
SAG-EX16 TTGATCAGTTCCTTCGTTGC AAAGGACTAAACTGTGGGGC 58 279
Figure  2.  Dark  adaptation  test  of  the
patient.  Fundus  photographs  of  the
patient  before  (A)  and  after  (B)  dark
adaptation. The fundus appearance was
characteristic  of  Oguchi  disease  with
grayish-yellow  discoloration  that  had
normal appearance after 2–3 h of dark
adaptation.
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1255The patient’s GRK1 sequence analysis did not reveal any
variants, but the SAG screening showed a novel homozygous
nonsense  mutation,  c.916G>T  (p.Glu306*),  in  exon  11
(Figure 3), which was not found in a healthy control panel
from the same population. Segregation analysis showed that
the mutated c.916G>T allele is inherited by descent, as the
patient’s (V:1) paternal and maternal grandmothers (III:4 and
III:2, respectively) are first cousins and were carriers of c.
916G>T (Figure 1). In addition, individuals IV:1 (maternal
uncle), IV:2 (mother), and V:2 (brother) were also carriers of
this mutation, while three members (IV:4 [paternal uncle], V:
3 [brother], and V:4 [sister]) were homozygous for the wild-
type sequence (Figure 1). The carriers of the mutation, the
patient’s mother (IV:2) and brother (V:2), did not have any
hematological or neurologic abnormalities.
The MTHFR C677T analysis showed that the patient (V:
1)  along  with  individuals  IV:1,  IV:2,  V:2,  and  V:4  were
heterozygous for this variation and had raised homocysteine
levels that ranged between 15.90 and 22.79 µmol/l, while the
wild-type homozygous CC individuals (III:4, IV:4, and V:3)
had normal homocysteine levels (<15 μmol/l; Table 2).
DISCUSSION
SAG belongs to the arrestin protein family, which are soluble
cytoplasmic proteins with four identified members (arrestin
1–4). Based on differences in their structure and function,
these four proteins are distributed into two sub-classes: the
visual and non-visual proteins. The visual proteins, arrestin 1
and 4, are expressed specifically in the retina, while arrestin
2 and 3 are ubiquitously expressed [19,20]. Among the visual
sub-family, arrestin 1 is rod specific, which is also known as
S-antigen (SAG) while arrestin 4 is cone specific and called
X arrestin. These visual arrestins are located in the rod or cone
outer  segment  where  they  bind  to  their  receptors
(phosphorylated rhodopsin/opsin proteins) to switch off the
rhodopsin/opsin-activated  phototransduction  cascade  [21].
Arrestin  knockout  mice  experience  photoreceptor  cell
degeneration  due  to  continuous  upregulation  of  the
phototransduction, as a result of the defective rhodopsin/opsin
shut-off mechanism [22]. This defective mechanism results in
Oguchi disease, a rare form of autosomal recessive congenital
stationary night blindness caused by mutations in the genes
Figure  3.  Sequence  chromatogram  of
SAG c.916G>T variant. Sequence trace
of part of exon 11 of SAG in the patient
carrying  the  homozygous  c.916T
mutation  which  is  indicated  by  a  red
arrow.
TABLE 2. MTHFR (C677T) POLYMORPHISM GENOTYPES AND FASTING HOMOCYSTEINE LEVELS OF THE FAMILY MEMBERS.
Individual Gender Age (years) MTHFR (C677T) genotype Serum fasting homocysteine (µmol/O
III:4 Female 70 CC 13.15
IV:1 Male 38 CT 18.58
IV:2 Female 40 CT 17.76
IV:4 Male 50 CC 14.78
V:1 Female 17 CT 21.4
V:2 Male 19 CT 22.79
V:3 Male 15 CC 10.50
V:4 Female 12 CT 15.90
The values in bold of homocysteine levels are greater than the normal range.
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1256coding for either SAG or GRK1, as both proteins are involved
in terminating the activation of the phototransduction cascade,
where SAG plays an important regulatory role while GRK1
functions as the phosphorylating enzyme [23,24].
Oguchi disease has been shown to be the most frequent
cause of congenital stationary night blindness in the Japanese
population, where the disease is frequently caused by only a
single base pair deletion (c.926delA; p.N309Tfs*12) in SAG
[4].  Apart  from  an  association  with  Oguchi  disease  and
retinitis  pigmentosa  (RP),  the  heterozygous  926delA  has
recently been shown to be involved in the manifestation of
variable clinical phenotype in a patient without stationary
night blindness [10]. In addition, though Sippel et al. [25]
observed several amino acid variants in SAG in patients with
RP, none of these segregated with the disease in the respective
families. Researchers have also observed that mutations in
SAG lead to the onset of RP in Oguchi patients at an advanced
stage of the disease, thus resulting in overlapping phenotypes
[26]. Figure 4 depicts the complete mutation spectrum of
SAG,  apart  from  a  frameshift  mutation;  all  previously
identified variants are nonsense mutations. To date, in the
Pakistani  population  there  have  been  no  reports  of  SAG
mutations causing Oguchi disease. In the present study, we
have identified a novel SAG variant (c.916G>T; p.Glu306*)
as  the  cause  of  Oguchi  disease  in  a  female  patient  who
inherited the mutation from a common ancestor of her parents.
The identified mutation is located in a conserved motif of the
C-domain of the protein (Figure 4) specifically involved in
receptor binding. The position of this nonsense mutation in
exon 11 suggests the resulting mRNA could be subject to
nonsense-mediated decay [27,28]. If a truncated protein is
synthesized,  the  terminal  portion  of  the  C-domain  that
normally spans amino acids 203 to 364 would be absent; thus,
this mutant protein would not be able to activate G proteins in
the visual cascade.
As the affected individual in the current study has not only
Oguchi disease but also DST, thrombocytopenia, and SLE, a
detailed  literature  search  was  performed  to  ascertain  the
correlation  among  ophthalmological,  neurologic,  and
hematological features. SLE is a multisystem autoimmune
connective tissue disorder with various clinical presentations
including  thrombocytopenia,  a  condition  caused  by
autoimmune platelet destruction, which is present in one third
of SLE cases [29]. DST represents blood clot formation inside
any of the dural sinuses in the brain. The co-occurrence of
DST with SLE has been seen in patients with DST-induced
benign intracranial hypertension syndrome in SLE patients
[30,31]. In addition, DST has been shown to be aggravated
due  to  heparin-induced  thrombocytopenia  as  well  as
thrombosis [32]. Therefore, there might be a contribution of
common genetic or environmental factors in the manifestation
of these three conditions (SLE, DST, and thrombocytopenia)
as they are all autoimmune-related disorders. One interesting
clinical aspect in this patient is hyperhomocysteinemia, which
points  toward  the  probable  involvement  of  this  factor  in
combination with other unknown factors in causing the onset
of non-ocular features in this patient. Several studies have
reported  the  association  of  hyperhomocysteinemia  with
autoimmune diseases such as SLE due to unknown factors
[33]. In addition, other studies have shown the association of
C677T  polymorphism  in  MTHFR  with  raised  serum
homocysteine levels [18,34,35]. The family members C677T
genotyping  revealed  an  association  of  this  SNP  with
hyperhomocysteinemia  in  the  family;  in  addition,  the
heterozygous  (CT)  individuals  had  raised  homocysteine
levels compared to the homozygous (CC) family members.
Several case-control association studies have shown that SLE
Figure 4. Mutation spectrum of SAG. The location of the known and new sequence variants are depicted above and below the gene (in cDNA
notation; upper panel) and protein (in amino acid notation; lower panel), respectively. Oguchi associated mutations are indicated in blue letters
while the Oguchi and retinitis pigmentosa associated mutation is shown in dark orchid color. The novel nonsense mutation (c.916G>T;
p.Glu306X) is depicted in black letters below the gene and the predicted protein, which hypothetically would result in a protein with a severely
truncated C domain.
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1257patients  with  hyperhomocysteinemia  are  susceptible  to
developing cardiovascular disease (CVD) later in life [33]; in
addition,  the  age  of  onset  of  CVD  in  the  South  Asian
population is above 50 years of age [36]. As the patient and
other  family  members  with  hyperhomocysteinemia  are
currently young, they might develop CVD later in life. We
must point out here that the genetic as well as biochemical
investigations into the onset of non-ocular findings in this
patient still need further elucidation. As SAG is expressed
specifically in the rod cells and pineal gland, in the absence
of  other  reported  Oguchi  cases  with  DST,  SLE,  and
thrombocytopenia, it is assumed that the non-ocular features
are not associated with the SAG variant.
In  conclusion,  we  have  identified  the  first  nonsense
mutation in the SAG gene in a patient with Oguchi type 1
disease in Pakistan.
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